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Background: Under-treated depression may be especially harmful in early adulthood. The aims of this study are to
describe treatments received for depressive disorders, to define factors associated with treatment adequacy and
dropouts from treatment in a Finnish general population sample of young adults.
Methods: A nationally representative two-stage cluster sample of 1894 Finns aged 19 to 34 years was sent a
questionnaire containing several mental health screens. All screen positives and a random sample of screen negatives
were invited to participate in a mental health assessment including a SCID interview. Case records from mental health
treatments for the same sample were obtained for the final diagnostic assessment. Based on all available information,
receiving antidepressant pharmacotherapy for at least two months with at least four visits with any type of physician or
at least eight sessions of psychotherapy within 12 months or at least four days of hospitalization were regarded
as minimally adequate treatment. Treatment dropout was rated if the treatment strategy was assessed to be
adequate according to the case records but the patient discontinued the visits.
Results: Of participants with depressive disorders (n = 142), 40.9% received minimally adequate treatment. In
multiple logistic regression models, substance use disorder and female gender were associated with at least one
visit with a physician, while having major depressive disorder was associated with visits with a physician at least
4 times a year. Women had higher odds of having received any psychotherapy and psychotherapy lasting for at
least 8 sessions in a year. Low education and a history of suicide attempt were associated with increased odds
of treatment dropout. None of the factors explained the final outcome of minimally adequate treatment.
Conclusions: Treatment adequacy in the present study was better than previously seen, but more efforts are
needed to provide adequate treatment for young adults, especially those with low education and suicidality.
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Depressive disorders are a leading cause of burden of
disease worldwide [1]. Mood disorders are also the most
costly disorders and depression the most burdensome
disorder of the brain in Europe, mainly because of high
indirect costs caused by disability [2-4]. However,
depressive disorders are still often unrecognized and
under-treated despite existing forms of effective treat-
ment [5-7].* Correspondence: teija.kasteenpohja@thl.fi
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unless otherwise stated.Untreated mental disorders are particularly harmful in
adolescence and early adulthood, since they limit work,
educational ability, and social interaction in a critical
life-stage of identity formation and socialization [8].
Though the prevalence of depression is at its peak dur-
ing this particular period [9-11], studies that focus on
young adults and depressive disorders and their treat-
ment are relatively rare. In the National Comorbidity
Survey Replication, Kessler also investigated the group
aged 18–29 and found a lifetime prevalence of 15.4% for
major depressive disorder and 1.7% for dysthymia [10].
Aalto-Setälä et al. presented a prevalence of 14.9% for
twelve-month depressive disorders among young urbanentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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them had had a contact with mental health services and
about one-third had reported treatment contacts during
the index episode [12]. Haarasilta et al. found that about
half of the subjects with MDE were estimated to be in
need of treatment but only 20.6% had sought care for
depression during the preceding year in a sample of 15–
24 year olds from the Finnish Health Care Survey of
1996 [13].
Studying adequate treatment is important because
guideline concordant depression care is associated with
better patient outcome [14,15]. However, Hepner et al.
found that primary care physicians could often detect
depression and initiate treatment but had difficulties in
completion of a minimal course of treatment for de-
pression [15]. Eisenberg et al. in turn investigated col-
lege students in the United States and found only 22%
of depressed students received minimally adequate
treatment [16].
Previous studies have shown that mental health treat-
ment dropout is a common problem [17-20] that may
limit treatment effectiveness [21,22] and be a sign of
poor clinical performance [23]. Therefore, understanding
how different risk factors are associated with dropout is
important for designing mental health services.
This study is based on a nationwide, representative
population-based sample of young Finnish adults aged
20–34. The aims of this study are to describe treatment
received for depressive disorders, treatment adequacy
and dropouts from treatment among young adults; to in-
vestigate sociodemographic correlates; and to identify
comorbid mental disorders and disorder-specific factors
that possibly affect treatment adequacy and dropout.
Methods
Sample
Data were derived from the Mental Health in Early
Adulthood in Finland (MEAF) study. Methods have been
reported in detail elsewhere [24]. MEAF is based on a
nationally representative two-stage cluster sample (n =
1894) of young adults aged 18–29 years in the Health
2000 study, which was a comprehensive health survey
where the original young adult assessment was carried
out in 2001. Although there were questions related also
to mental health in the Health 2000 young adult proto-
col, a structured diagnostic interview was not conducted
[25-27]. Therefore, a substudy focusing on mental health
(MEAF) was launched. Study designs of Health 2000 and
MEAF are described in more detail in Additional file 1:
Methods.
The study flow of the MEAF study is presented in
Figure 1. A questionnaire was mailed 2–4 years after the
original study to all members of the young adult sample,
excluding those who had died or refused furthercontacts. Participants were aged 20–34 during this time
period. The questionnaire included several scales asses-
sing mental health and substance use: K10 [28] and the
GHQ-12 [29] for general psychological distress, SCOFF
[30] for eating disorders, 22 questions on delusions and
hallucinations for psychotic disorders from the CIDI
interview [31], the MDQ [32] for manic symptoms, and
CAGE [33] for alcohol abuse. Persons who reported
symptoms above a defined threshold in any screening
scale were asked to participate in the mental health
interview. Information from the Finnish National
Hospital Discharge Register (NHDR) was used to iden-
tify all persons who had received hospital treatment due
to any mental disorder [International Classification of
Diseases (ICD)-10 section F, ICD-8 and ICD-9 290–319]
and they were asked to participate in the interview. In
addition, a random subsample of Health 2000 young
adults was invited to the interview regardless of their an-
swers to the screening questionnaire. Persons selected
via NHDR who had not returned the MEAF question-
naire were contacted through the person responsible for
the treatment, usually their general practitioner or
psychiatrist. Screening instruments and their cut-off
points are shown in Table 1. The screening procedure
and selection of the cut-off points for each screen are
described in detail in Additional file 1: Methods. [24].
The ethics committees of the National Public Health
Institute (since 2009 the National Institute of Health
and Welfare) and the Hospital District of Helsinki and
Uusimaa approved the Health 2000 survey and the
MEAF reassessment. Participants provided written in-
formed consent [24,25].
Mental health assessment
The mental health interview was conducted using the
research version of the Structured Clinical Interview for
DSM-IV (SCID-I) [34]. The sections on mood, psych-
otic, substance use, anxiety and eating disorders were in-
cluded in the assessment. The SCID Screening module
was used at the beginning of the interview to enhance
reliability [35].
The assessment began with a neuropsychological test
battery [36] followed by the mental health interview.
The interview started with questions on sociodemo-
graphic factors and treatment received for mental health
problems, followed by the SCID-I interview and ques-
tions assessing the lifetime occurrence of suicidal idea-
tion and behavior, the Global Assessment of Functioning
(GAF), and the Social and Occupational Functioning
Assessment Scale (SOFAS) [37]. The assessments were
carried out by experienced research nurses or psycholo-
gists who attended a one-week training period and regu-
lar follow-up sessions. All interviews were reviewed by
the interviewer together with a psychiatrist.
Table 1 Screens used for selecting persons to mental health interview
Screen Symptoms that the screen
assesses
Cut-off point or criterion
for selection
Number (%) of persons
selected by the screen
General Health Questionnaire (GHQ-12) Psychological distress
(past month)
>3 245 (18.6%)a
K10 Psychological distress
(past month)
>18 215 (16.3%)a
SCOFF Eating disorders (current) >1 127 (9.7%)a
CIDI section G (psychotic symptoms) Psychotic disorders (lifetime) At least one symptom 348 (26.4%)a
Mood Disorder Questionnaire (MDQ) Bipolar spectrum disorders
(lifetime)
>6 170 (12.9%)a
CAGE Alcohol use disorders (lifetime) >2 229 (17.4%)a
Use of any illicit drug Substance use disorders (lifetime) At least 6 times 98 (7.4%)a
Suicide attempt Severe suicidality At least one attempt 46 (3.5%)a
Use of health services for mental health
problem
All lifetime disorders At least once 239 (18.2%)a
Perceived need for treatment All lifetime disorders Self-reported need for treatment 90 (6.8%)a
Hospitalization due to any mental health
disorder
All lifetime disorders ICD-10 group F or ICD-8 and ICD-9
290-319
120 (6.3%)b
aN = 1316 (participants who returned a questionnaire including screens).
bN = 1894 (all participants aged 18–29 years in the Health 2000 study).
Health 2000 young adult study sample (N = 1894)
Baseline study 2001
Died N = 5
Refused further contact N = 26
MEAF questionnaire sent
Years 2003-2005
N = 1863
Not reached N = 274
Refused N = 180
Did not return questionnaire N = 93
MEAF questionnaire returned
N = 1316
Invited to participate in the MEAF assessment
N = 982
Not reached N = 5
Refused N = 431
MEAF mental health assessment completed
Years 2003-2005
N = 546 
Figure 1 Mental Health in Early Adulthood in Finland (MEAF) study flow. Adapted from Suvisaari et al. 2009 [24], courtesy of Cambridge
University Press.
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the interview. The post-interview questionnaire sought
further information on the person’s mental health and
associated factors.
Final diagnostic assessment
For the final diagnostic assessment, all case records from
hospital and outpatient treatment were obtained with
the participant’s approval. Permission to view the case
records of non-participants was obtained from the
Finnish Ministry of Social Affairs and Health, excluding
those who had refused any participation in the Health
2000 study. Case records were compiled using informa-
tion from the Hospital Discharge Register, self-reported
mental health care contacts, and primary health care
centers. The aim was to gather information on all life-
time treatments for mental health disorders.
The final best-estimate diagnoses using DSM-IV-TR
criteria were made by four experienced clinicians (J.S., T.
A.-S., S.S., J.P.). Diagnostic assessment was based on all
available systematically evaluated information from the
interview and/or case records. Disorders not covered by
SCID-I were also evaluated, including personality disor-
ders. The reliability of the diagnoses was tested on 40
cases rated by all four clinicians. Unweighted Kappa
values between each pair of raters ranged from 0.94 to
1.00 for major depressive disorder and from 0.90 to 1.0
for any depressive disorder [24].
The lifetime prevalence of depressive disorders (i.e.
major depressive disorder, dysthymia or depressive dis-
order NOS) in this sample was 17.7% [24]. This paper
investigates this subgroup which consisted of 142 partic-
ipants after excluding those with a diagnosis of schizo-
phrenia spectrum disorders (3 persons).
Use of mental health services and treatment received
From mental health interviews and case records we
gathered information on mental health care use as well
as treatment received. All data were collected on both
the most recent and the most intensively treated episode
of depression. It turned out, however, that they differed
only in 18 cases (12.7%). Our aim was to investigate the
average as well as the most recent functioning of the
health care system. Therefore, the present paper focuses
on treatment received during the most recent depressive
episode. The distribution of sociodemographic and
disorder-specific factors, comorbid psychiatric disorders
and treatments received and dropouts during the most
intensively treated depressive episode are available in the
Additional file 2: Table S1, Additional file 3: Table S2
and Additional file 4: Table S3.
We determined criteria for minimally adequate treat-
ment according to evidence-based guidelines [38,39].
Based on this information, receiving antidepressantpharmacotherapy for at least two months with at least
four visits with any type of physician or at least eight
sessions of psychotherapy within 12 months were
regarded as minimally adequate treatment. The same
criteria were used in the European Study of the Epidemi-
ology of Mental Disorders and the National Comorbidity
Survey Replication [40,41]. We also defined at least four
days of hospitalizations for depression as adequate care.
The criteria are described in detail in Additional file 1:
Methods.
Visits with physicians related to depressive symptoms
were assessed from case records and interviews and di-
vided into three categories: none, at least one visit or at
least four visits within 12 months. We also included in
visits a telephone consultation between a patient and
physician as well as consultations between health care
professionals and the treating physician that concerned
the patient’s treatment.
A psychotherapeutic session was defined as a visit with
a psychiatrist, psychologist or psychotherapist in all set-
tings or a visit with any professional in a psychiatric
clinic. We counted the sessions of psychotherapy and di-
vided them into three categories: none, at least one ses-
sion, or at least eight sessions within a year.
Pharmacotherapy was evaluated for the type and dur-
ation. The information about antidepressant use was di-
vided into three categories: not prescribed, prescribed or
used for at least two months. We also gathered informa-
tion about hospitalizations, their cause and duration.
We rated treatment dropout if the treatment strategy
was assessed to be adequate according to the case re-
cords but the patient discontinued the visits by his own
decision. A definition of treatment dropout is described
in more detail in Additional file 1: Methods.
Case records were ordered from 99 participants with
depressive disorder based on either self-reported out-
patient treatment contact or register information on
hospital treatments. They were received for 86 (86.9%)
of them, whereas in 13 cases the records were not found.
In these cases, the quality of care was coded based on
information from the interview which included ques-
tions about the type, frequency and duration of
treatment.Sociodemographic, disorder-specific and comorbid
factors
Information on sociodemographic and disorder specific
factors and comorbid psychiatric disorders was gathered
in the mental health interview and from case records.
Based on this information, we also defined broadly the
start and end points for depressive episodes and formed
new variables concerning the duration of depression and
age at the onset of illness.
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factors and treatment using the following variables:
gender, marital status, age at the time the MEAF-
questionnaire was sent (19–24 years, 25–29 years and
30–34 years old), basic education (less than high school/
high school) and current employment (employed, student,
unemployed, other). High school means twelve years of
education followed by a matriculation examination. For
the “other” employment group, 5.6% (1) were on disability
pension and 94.4% (17) were at home taking care of
household and family members. We examined the effect
of basic education only, since some of the younger mem-
bers of the cohort had not yet finished their vocational or
higher education.
We studied whether disorder-specific factors such as
the severity of disease (i.e. MDD or not) and duration of
depression affected the treatment adequacy. The effect
of a lifetime history of suicide attempts was examined
based on self-reported suicide attempts in the question-
naire and/or interview or suicide attempts according to
case records, as described by Suokas and collegues [42].
The impact of comorbid psychiatric disorders on treat-
ment was examined for the other three main categories
of non-psychotic disorders: anxiety disorders, substance
use disorders, and eating disorders.
Statistical analysis
We used standard statistical methods to generate
descriptive statistics. Since the analysis was limited to
the subgroup of depressive participants, we did not use
survey weights in the analysis. The associations of the
following sociodemographic factors with treatments re-
ceived were analyzed: gender, age, basic education, em-
ployment and marital status. We also examined whether
suicidality, duration of depressive episode, having a diag-
nosis of MDD, or comorbid psychiatric disorders af-
fected the treatment adequacy. The relationship of all
these variables was examined separately for different
components of care, i.e. pharmacotherapy, physician
visits, psychotherapy and finally the overall treatment
adequacy. We also examined what kind of patients had
the highest risk of discontinuing treatment. Differences
were tested using the χ2 or Fisher’s exact tests when ap-
propriate. Logistic regression analyses were used to iden-
tify variables that were independently associated with
the use of mental health services and the type and ad-
equacy of treatment. Gender, age, age at the onset of de-
pression (continuous), basic education, history of
suicidal attempts, diagnosis of MDD, comorbid anxiety
disorder and substance use disorder were entered simul-
taneously into a logistic regression model to explore the
factors affecting treatment. Values of p < 0.05 were con-
sidered statistically significant. The SAS 9.3 statistical
package was used in the analyses.Results
Participants
Table 2 shows the socio-demographic, disorder-specific
and comorbid psychiatric disorder factors of the partici-
pants. Male participants with any diagnosis of life-time
depressive disorder numbered 45 (31.7%) and female
participants 97 (68.3%). There was a statistically signifi-
cant difference in basic education and current employ-
ment between the genders. Of the comorbid psychiatric
disorders men had more substance use disorders and
women had more eating disorders. A median time be-
tween the beginning of the last depressive episode and
the survey was 2.3 years, ranging from 0 to 23.6 years.
10.6% (15) of participants were still (during the last
month before the interview) in their most recent
episode.Treatment received and treatment adequacy
Of all participants with depressive disorder, 76.1% had
had some kind of contact with the health care system
for their depression. More than two thirds had visited a
physician and 28.5% had had at least four visits within a
year. Antidepressive medication was prescribed to 43.7%
and almost a third had used antidepressants for at least
two months. Guideline-concordant pharmacotherapy
was received by 17.6% of participants. Almost 60% of
subjects had attended psychotherapy sessions, a third at
least eight times a year. Any hospital treatment was re-
ceived by 9.2% and at least 4 days of hospitalization by
7.0% of all participants. A total of 40.9% of subjects had
received minimally adequate treatment (Table 3).Socio-demographic factors and treatment received
An association was found between adequate psychother-
apy and gender as well as current employment in the bi-
variate analysis. Women had more often than men
attended at least eight sessions of psychotherapy a year.
Individuals who were currently students or in the cat-
egory “other” had more often received psychotherapy at
least eight times a year than the rest of the sample
(Table 3).
Basic education was statistically significantly associated
with appointments with physicians in the bivariate ana-
lysis: the proportion of individuals who had no visits
with a doctor was higher among those who had com-
pleted high school than among those with less
education.
Age at the time of the study had an association with
different aspects of treatment in the bivariate analysis:
the youngest age group had received most forms of
treatment as well as minimally adequate treatment more
often than the older participants (Table 3).
Table 2 Socio-demographic and disorder specific factors and comorbid psychiatric disorders of participants
All Men Women
100.0% N = 142 31.7% N = 45 68.3% N = 97
Variable Category % N % N % N pb
Age <25 years 21.8 31 20.0 9 22.7 22
25-29 years 37.3 53 40.0 18 36.1 35
≥30 years 40.9 58 40.0 18 41.2 40 0.8873
Basic education Less than high school 50.7 69 64.1 25 45.4 44
High school 49.3 67 35.9 14 54.6 53 0.0480
Married or cohabiting Yes 50.4 69 42.5 17 53.6 52
No 49.6 68 57.5 23 46.4 45 0.2371
Current employment Employed 58.4 80 70.0 28 53.6 52
Student 21.2 29 15.0 6 23.7 23
Unemployed 7.3 10 15.0 6 4.1 4
Othera 13.1 18 0.0 0 18.6 18 0.0025
Major depressive disorderd Yes 78.2 111 80.0 36 77.3 75
Noe 21.8 31 20.0 9 22.7 22 0.7190
Suicide attempts Yes 12.0 17 15.6 7 10.3 10
No 88.0 125 84.4 38 89.7 87 0.3703
Duration of depression > 1 year Yes 33.9 41 29.4 10 35.6 31
No 66.1 80 70.6 24 64.4 56 0.5158
Comorbid anxiety disorderd Yes 32.4 46 31.1 14 33.0 32
No 67.6 96 68.9 31 67.0 65 0.8239
Comorbid substance use disorderd Yes 19.0 27 42.2 19 8.3 8
No 81.0 115 57.8 26 91.8 89 <0.0001
Comorbid eating disorderd Yes 8.5 12 0.0 0 12.4 12
No 91.6 130 100.0 45 87.6 85 0.0099c
aOf the other group, 5.6% (1) were on disability pension and 94,4% (17) at home taking care of household and family members.
bThe p-values indicate a significance of the difference between genders in the distribution of each catergory tested by χ2- or Fisher’s exact test. P-values < 0.05
in boldface.
cFisher’s exact test was used in the analysis.
dDiagnosis is a lifetime diagnosis.
eDysthymia or depressive disorder NOS.
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and treatment received
The relationship between treatment received and
disorder-specific factors and comorbidity is presented in
Table 4. Having a diagnosis of MDD was related to anti-
depressant medication for at least two months and phys-
ician visits at least four times a year in the bivariate
analysis. Duration of depressive episode was related to
minimally adequate treatment and appropriateness of
care in every aspect.
In the bivariate analysis of comorbid disorders, only
substance use disorder was associated statistically signifi-
cantly with treatment: participants with substance use
disorder had at least one visit with a physician more
often than others. There was also a trend in the direc-
tion of an association between substance use and any
pharmacotherapy (p = 0.069). The same kind of trendwas seen in the association between comorbid anxiety
disorder and having at least two months of pharmaco-
therapy (p = 0.061) and having at least one visit with a
physician (p = 0.064).
In our study group, 15.7% dropped out of treatment
(Table 3). Participants with less education, a history of
suicide attempts, or substance use disorder interrupted
their treatment more often than others according to the
bivariate analysis (Tables 3 and 4).
Factors associated with treatment and dropout in
multivariate analyses
In the multivariate analysis having a diagnosis of MDD
was associated with increased odds for visits with a
physician at least four times a year (OR 5.44, CI 1.40–
20.12, P = 0.014) (Table 5). This difference was not seen
in the analysis concerning the most intensively treated
Table 3 Sociodemographic factors, treatments received and dropouts during the most recent depressive episodei
Pharmacotherapy Visits with a physician/
a year
Guideline-concordant
pharmacotherapyc
Sessions of
psychotherapy/a year
Minimally
adequate
treatmente
Treatment
dropoutf
Anya ≥2 months Anyb ≥4 times Anyd ≥8 times
Variable Category N % N % N % N % N % N % N % N % N % N
All 142 43.7 62 31.6 43 67.2 92 28.5 39 17.6 25 59.6 84 33.3 47 40.9 58 15.7 18
Gender Male 45 46.7 21 38.1 16 59.1 26 29.6 13 20.0 9 53.3 24 20.0 9 35.6 16 22.9 8
Female 97 42.3 41 28.7 27 71.0 66 28.0 26 16.5 16 62.5 60 39.6 38 43.3 42 12.5 10
pg 0.6229 0.2775 0.1670 0.8474 0.6099 0.3012 0.0215 0.3824 0.1596
Agegroup <25 years 31 64.5 20 46.7 14 80.7 25 38.7 12 35.5 11 71.0 22 54.8 17 61.3 19 15.4 4
25-29 years 53 28.3 15 19.2 10 52.9 27 27.5 14 13.2 7 54.7 29 26.4 14 32.1 17 14.0 6
≥30 years 58 46.6 27 35.2 19 72.7 40 23.6 13 12.1 7 57.9 33 28.1 16 37.9 22 17.4 8
pg 0.0046 0.0280 0.0183 0.3241 0.0125 0.3235 0.0157 0.0266 0.9045
Basic Less than high school 69 47.8 33 32.8 21 76.1 51 32.8 22 17.4 12 60.3 41 33.8 23 43.5 30 22.2 12
education High school 67 35.8 24 27.3 18 56.9 37 20.0 13 14.9 10 56.7 38 32.8 22 35.8 24 3.6 2
pg 0.1560 0.4908 0.0193 0.0949 0.6962 0.6731 0.9031 0.3615 0.0033
Current Employed 80 37.5 30 25.0 19 65.4 51 25.6 20 11.3 9 57.0 45 26.6 21 36.3 29 12.5 8
employment Student 29 55.2 16 41.4 12 71.4 20 35.7 10 27.6 8 65.5 19 48.3 14 51.7 15 12.0 3
Unemployed 10 20.0 2 11.1 1 40.0 4 10.0 1 10.0 1 30.0 3 10.0 1 10.0 1 37.5 3
Other 18 50.0 9 41.2 7 76.5 13 23.5 4 22.2 4 66.7 12 50.0 9 50.0 9 0.0 0
pg 0.1580 0.1542 0.2374 0.4702h 0.1566h 0.2138 0.0260 0.0842 0.1131h
Married or No 68 39.7 27 26.2 17 60.0 39 23.1 15 17.7 12 53.7 36 34.3 23 39.7 27 8.8 5
cohabiting Yes 69 43.5 30 33.3 22 72.1 49 29.4 20 14.5 10 62.3 43 31.9 22 39.1 27 16.7 9
pg 0.6542 0.3689 0.1418 0.4069 0.6151 0.3102 0.7620 0.9451 0.2105
aAntidepressant prescribed.
bAt least 1 visit with a physician a year.
cAntidepressant used for at least 2 months + 4 visits with a physician a year.
dAt least 1 session of psychotherapy a year.
eAntidepressant used for at least 2 months + at least 4 visits with a physician a year or at least 8 sessions of psychotherapy a year or a hospitalization for depressive symptoms lasting for at least 4 days.
fA participant discontinued the visits despite adequate treatment plan.
gThe p-values indicate a significance of the difference between categories in a distribution of treatments and dropout tested by χ2- or Fisher’s exact test. P-values < 0.05 in boldface.
hFisher’s exact test was used in the analysis.
iA bivariate analysis.
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Table 4 Disorder-specific factors, comorbid psychiatric disorders, treatments received and dropouts during the most recent depressive episodei
Pharmacotherapy Visits with physician/
a year
Guideline-concordant
pharmacotherapyc
Sessions of psychotherapy/
a year
Minimally adequate
treatmente
Treatment
dropoutf
Anya ≥2 months Anyb ≥4 times Anyd ≥8 times
Variable Category N % N % N % N % N % N % N % N % N % N
Major Yes 111 46.9 52 36.1 39 69.8 74 33.0 35 20.7 23 61.8 68 35.5 39 43.2 48 14.8 13
depressive disorder No 31 32.3 10 14.3 4 58.1 18 12.9 4 6.5 2 51.6 16 25.8 8 32.3 10 18.5 5
pg 0.1476 0.0269 0.2206 0.0290 0.0651 0.3065 0.3142 0.2713 0.7623h
Duration of Yes 41 70.7 29 60.0 24 84.6 33 46.2 18 36.6 15 77.5 31 65.0 26 68.3 28 20.6 7
episode >1 year No 80 28.8 23 18.0 14 60.3 47 18.0 14 8.8 7 48.8 39 21.3 17 26.3 21 9.2 6
pg <.0001 <.0001 0.0076 0.0013 0.0002 0.0026 <.0001 <.0001 0.1276h
Suicide attempts Yes 17 58.8 10 41.2 7 81.3 13 43.8 7 23.5 4 76.5 13 17.7 3 29.4 5 60.0 6
No 125 41.6 52 30.3 36 65.3 79 26.5 32 16.8 21 57.3 71 35.5 44 42.4 53 11.4 12
pg 0.1791 0.3649 0.2014 0.2360h 0.5019h 0.1301 0.1435 0.3067 9.286E-04h
Comorbid Yes 46 50.0 23 42.2 19 77.8 35 37.8 17 23.9 11 67.4 31 34.8 16 43.5 20 21.1 8
anxiety disorder No 96 40.6 39 26.4 24 62.0 57 23.9 22 14.6 14 55.8 53 32.6 31 39.6 38 13.0 10
pg 0.2918 0.0614 0.0641 0.0912 0.1719 0.1881 0.7995 0.6586 0.2628
Comorbid Yes 27 59.3 16 45.8 11 84.0 21 40.0 10 18.5 5 69.2 18 23.1 6 40.7 11 38.9 7
substance use disorder No 115 40.0 46 28.6 32 63.4 71 25.9 29 17.4 20 57.4 66 35.7 41 40.9 47 11.3 11
pg 0.0694 0.0989 0.0473 0.1576 1.0000h 0.2666 0.2193 0.9902 0.0080h
Comorbid Yes 12 50.0 6 33.3 4 90.9 10 45.5 5 25.0 3 50.0 6 41.7 5 41.7 5 11.1 1
eating disorder No 130 43.1 56 31.5 39 65.1 82 27.0 34 16.9 22 60.5 78 32.6 42 40.8 53 16.0 17
pg 0.6436 1.0000h 0.1013h 0.2931h 0.4432h 0.5458h 0.5342h 1.0000h 1.0000h
aAntidepressant prescribed.
bAt least 1 visit with a physician a year.
cAntidepressant used for at least 2 months + 4 visits with a physician a year.
dAt least 1 session of psychotherapy a year.
eAntidepressant used for at least 2 months + at least 4 visits with a physician a year or at least 8 sessions of psychotherapy a year or a hospitalization for depressive symptoms lasting for at least 4 days.
fA participant discontinued the visits despite adequate treatment plan.
gThe p-values indicate a significance of the difference between categories in a distribution of treatments and dropout tested by χ2- or Fisher’s exact test. P-values < 0.05 in boldface.
hFisher’s exact test was used in the analysis.
iA bivariate analysis.
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Table 5 Logistic regression models of variables associated with treatments received and dropout during the depressive episodeg, f
Pharmacotherapy Visits with a
physician/a year
Guideline-
concordant
pharmacotherapyc
Sessions of
psychotherapy/a year
Minimally
adequate
treatmente
Treatment
dropoutf
Anya ≥2 months Anyb ≥4 times Anyd ≥8 times
Variable Category OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Gender Male (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
Female 1.42 0.58-3.49 0.89 0.34-2.30 **4.45 1.58-12.54 2.01 0.67-6.01 0.97 0.30-3.13 *2.53 1.04-6.16 *3.37 1.20-9.46 2.15 0.86-5.34 2.67 0.42-17.06
Agegroup <25 years (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
25-29 years **0.20 0.07-0.57 *0.30 0.10-0.92 **0.18 0.05-0.63 0.89 0.28-2.81 0.32 0.09-1.13 0.56 0.20-1.60 0.39 0.14-1.14 0.36 0.13-1.01 1.80 0.23-14.07
≥30 years 0.40 0.12-1.28 0.67 0.20-2.27 0.36 0.09-1.45 0.67 0.18-2.45 0.28 0.06-1.27 0.61 0.18-1.99 0.44 0.13-1.49 0.63 0.20-2.02 2.43 0.23-25.40
Age at the
onset of
Continuous 1.02 0.93-1.12 1.00 0.90-1.11 1.08 0.97-1.20 0.95 0.86-1.06 1.00 0.88-1.14 0.98 0.90-1.08 0.99 0.89-1.09 0.96 0.87-1.05 0.95 0.79-1.14
depression
Basic
education
Less than high
school (ref.)
1.00 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
High school 0.78 0.36-1.72 1.02 0.43-2.40 0.47 0.20-1.14 0.57 0.23-1.38 1.10 0.39-3.08 1.01 0.47-2.18 0.80 0.36-1.79 0.66 0.30-1.45 *0.15 0.03-0.86
Major No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
depressive
disorder
Yes 1.90 0.74-4.87 2.66 0.81-8.77 2.00 0.77-5.24 *5.44 1.40-21.12 3.21 0.66-15.48 1.79 0.75-4.25 1.40 0.54-3.63 1.59 0.63-3.97 1.21 0.24-6.12
Suicide
attempts
No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
Yes 1.14 0.33-3.86 0.84 0.23-3.15 0.88 0.19-4.08 1.89 0.51-6.96 1.65 0.36-7.66 1.74 0.47-6.46 0.43 0.11-1.80 0.39 0.10-1.43 *6.73 1.10-41.17
Comorbid No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
anxiety
disorder
Yes 1.25 0.56-2.79 1.85 0.80-4.27 1.72 0.67-4.44 1.59 0.67-3.78 1.88 0.69-5.12 0.78 0.35-1.73 1.19 0.52-2.71 0.83 0.38-1.83 1.66 0.44-6.31
Comorbid
substance
No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
use disorder Yes 2.66 0.85-8.32 1.91 0.57-6.47 **8.29 1.69-40.58 2.51 0.70-9.02 0.99 0.22-4.49 2.80 0.84-9.35 1.36 0.39-4.78 1.75 0.56-5.42 3.69 0.56-24.52
*p < 0.05; **p < 0.01. These p-values indicate a significance of the difference of the odds ratios between categories tested by χ2-test.
aAntidepressant prescribed.
bAt least 1 visit with a physician a year.
cAntidepressant used for at least 2 months + 4 visits with a physician a year.
dAt least 1 session of psychotherapy a year.
eAntidepressant used for at least 2 months + at least 4 visits with a physician a year or at least 8 sessions of psychotherapy a year or a hospitalization for depressive symptoms lasting for at least 4 days.
fA participant discontinued the visits despite adequate treatment plan.
gThe most recent depressive episode.
f All the variables were entered simultaneously into a logistic regression model.
OR = Odds ratio; 95% CI = 95% confidence interval.
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completed high school had lower odds of visiting a
physician at least four times a year (Additional file 4:
Table S3). Substance use disorder (OR 8.29, CI 1.69–
40.58, P = 0.009) and female gender (OR 4.45, CI 1.58–
12.54, P = 0.005) were associated with at least one visit
with a physician.
Women had higher odds of having any psychotherapy
(OR 2.53, CI 1.04–6.16, P = 0.041) and at least 8 sessions
of psychotherapy a year (OR 3.37, CI 1.20–9.46, P =
0.021) (Table 5). In the most intensively treated depres-
sive episode the same kind of trend towards womens’
higher odds of having psychotherapy was seen, but the
p-values were just above the significance limit
(Additional file 4: Table S3). Concerning age, those aged
25–29 had the lowest odds of having any medication
(OR 0.20, CI 0.07–0.57, P = 0.003) and guideline-
concordant medication (OR 0.30, CI 0.10–0.92, P =
0.035) as well as at least one visit with a physician (OR
0.18, CI 0.05–0.63, P = 0.008) compared to the youngest
age group. None of these factors explained the final out-
come of minimally adequate treatment (Table 5).
The explanatory factors above were also used in the
logistic regression model to examine treatment dropout.
In the multivariate analysis persons who had graduated
from high school had a lower odds of dropping out of
treatment (OR 0.15, CI 0.03–0.86, P = 0.033). Lifetime
history of suicide attempts was associated with increased
odds of treatment interruption (OR 6.73, CI 1.10–41.17,
P = 0.039) (Table 5). The latter difference was not statis-
tically significant in the multivariate analysis concerning
the most intensively treated depressive episode
(Additional file 4: Table S3).
Discussion
Compared to previous Finnish studies, treatment of de-
pressive disorders has improved among young adults
[12,13,43]. A similar trend was seen in Canada [44]. In
our study of young adults with depressive disorders,
76.1% had had some kind of contact because of their
depressive symptoms with the health care system during
the most recent depressive episode and 40.9% had
received minimally adequate treatment, as based on
international guidelines. In most studies concerning the
treatment adequacy of depressive disorders the propor-
tion has been much lower. In the National Comorbidity
Survey Replication study, only 21.7% of all respondents
meeting the 12-month major depressive disorder criteria
received adequate treatment in the year of the interview
[6]. Gonzalez et al. found a very similar figure (21.3%)
when he investigated the use of guideline-concordant
depression care among adults with 12-month MDE in
the United States, though the definition of adequate
treatment was less strict than ours in that they onlyrequired four psychotherapy visits [45]. In Canada,
Duhoux et al. found that 29.1% of subjects with MDE
during the 12 months preceding the survey had received
minimally adequate treatment according to criteria
which were close to ours [14]. However, detailed com-
parisons between countries are difficult because of lack
of relevant and valid comparable data on mental health
services [46].
The high proportion of adequate treatment in our
study may be explained partly by our versatile informa-
tion search. We gathered information also from case re-
cords, while most surveys have used only interviews,
which may be influenced by memory bias. Our partici-
pants were young and we investigated the most recent
depressive episode, and these factors also support the
conclusion that memory bias is not a major problem in
this study. A slight increase in our figure may be caused
by our definition of a visit with a physician, which also
included consultations by telephone and by another
health care professional. In addition, we defined at least
four days of hospitalizations as adequate. These cases,
however, were few (10 participants) and half of them
had received adequate treatment also in outpatient care.
None of the factors chosen were related to the overall
adequacy of treatment in a multivariate analysis. This
suggests that services for the treatment of depression are
not functioning efficiently: people with more severe or
comorbid symptoms did not receive adequate treatment
more often than others. This is alarming, because ac-
cording to previous studies both severity of depression
and comorbidity are associated with worse long-term
outcome of depression [47,48]. In terms of health equity,
it is encouraging that sociodemographic factors were not
associated with receiving minimally adequate treatment.
However, in a bivariate analysis, the duration of depres-
sive episode was related to treatment such that partici-
pants whose episode had lasted over a year received
more often any care and guideline-concordant care in
regard to all the various aspects of treatment as well as
minimally adequate treatment. This is in line with previ-
ous epidemiological studies that have shown that longer
duration of depressive episode is related to treatment
referral [6,49-51]. In a study among adolescents and
young adults, Wittchen et al. found that participants
with dysthymia and recurrent depression had sought
help more often (46% and 40%) than participants with a
single episode of depression (24%) [8]. Wang et al. found
that delays in initial help-seeking is a pervasive problem
worldwide, with median delays in making contact ran-
ging from 1.0 to 14.0 years for mood disorders [52].
Thus, a likely reason for the lower extent of treatment
for those who have suffered for a shorter period is that
they have not yet sought help. This may also be one ex-
planation for a higher estimate of treatment adequacy in
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ies: we investigated the most recent lifetime depressive
episode whereas many other studies have looked at de-
pressive episodes within the last 12 months. It is likely
that in other studies, all participants with depressive dis-
order had not yet sought help though they would do so
in the future.
It has previously been shown that the severity of de-
pression is also associated with treatment referral
[6,7,43,50,53,54]. In this study, having a diagnosis of
MDD represented the severity of illness and was associ-
ated with having some forms of treatment, especially
guideline-concordant physician visits. So it seems that
physicians tend to meet the most complicated cases
more often than others, as an association between co-
morbid substance use disorder and physician visits was
also found. This suggests that referral to treatment
works better for these groups with more serious illness
and comorbidity, although they did not receive minim-
ally adequate treatment more often than other partici-
pants with depressive disorder.
Women more often received guideline-concordant
psychotherapy than men and this difference was statisti-
cally significant even after adjusting for other factors. In
the multivariate analysis, female gender was also related
to having any psychotherapy and having visited a phys-
ician. Unlike in our study, Hämäläinen et al. found that
female gender was associated with the use of antidepres-
sants but not with psychological treatment among par-
ticipants with MDD in the Health 2000 adult sample
[43]. However, many previous studies have similarly
found a relation between female gender and more fre-
quent use of psychotherapy [55,56], a greater likelihood
to use any 12-month mental health services [7,57] and
guideline-concordant treatment from mental health spe-
cialists [54]. It has been suggested that women are more
likely to seek, accept and continue treatment because of
their reduced perception of stigma and better ability to
translate feelings of distress into conscious recognition
of having emotional problems [58].
The annual prevalence of antidepressant use and
long-term treatment increased between 1994 and 2003
in Finland [59]. We found in our study that 46.9% of
subjects with MDD received some antidepressant
pharmacotherapy and 36.1% used medication at least
for two months. In the adult sample of the Health 2000
study, only 24% of individuals with MDD were cur-
rently receiving antidepressants [43]. In the sample of
adolescents and young adults from the Finnish Health
Care Survey 1996, only 14% of subjects with MDE re-
ported recent use of antidepressants [13]. According to
these figures use of pharmacotherapy has increased re-
cently in Finland and is more frequent among young
people than previously.In our study group, 15.7% of participants dropped out
from treatment. In previous studies the rates of disen-
gagement from mental health services have varied from
4–46%, depending on the study setting, service type, and
definition of engagement used [60,61]. Our definition of
dropout was quite strict, requiring a proper treatment
plan. Pinto-Meza et al. studied treatment dropout
among patients with depression and anxiety in Europe
and found a dropout rate of 14% during a 12-month
period [19], which is in line with our figure. In the
bivariate analysis we found an association between drop-
outs and lower education, suicide attempts and comor-
bid substance use disorder, of which lower education
and suicidality remained statistically significant also in
the multivariate analysis. It is noteworthy that according
to the bivariate analysis, groups with less education and
substance use disorder had more often visited a phys-
ician at least once. Of these factors, substance use
disorder remained significant also after adjustment. So it
seems that these problematic subgroups with less educa-
tion, suicidality and substance use disorder—who are
otherwise at risk of social exclusion—are offered treat-
ment but do not receive the intended care because they
often drop out.
Strengths and limitations
The two-phase study design enabled us to conduct
SCID-I interviews requiring clinical judgment. These
were complemented by case records from mental health
treatment contacts. Thus the final diagnostic assessment
was based on all the available information, which is ex-
ceptional in population-based studies and a key strength
of the present study. Using multiple sources of informa-
tion also in regard to treatments compensated for any
possible effect of recall bias. On the other hand this
means that our results are not directly comparable with
the results of most previous surveys using only informa-
tion collected by interviews. However, the percentage of
minimally adequate treatment was only slightly smaller
(38.6%) when we excluded those patients who had not
been interviewed.
The limitation of a two-phase study design is attrition
[62]. In this study, nonresponse occurred in both the
questionnaire and the interview. Nonresponse in the
MEAF questionnaire depended on age, gender, and edu-
cation, but not on self-reported mental health disorders
at the baseline survey. Persons with a lifetime hospital
treatment for mental health problems returned the ques-
tionnaire less often, but this was compensated for by
medical records that we obtained. These factors were
also most strongly related to attrition in the interview.
None of the scores in any of the questionnaire screens
we used for the mental health interview differed between
interview participants and non-participants. More
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[24]. Another significant limitation was the small size of
study sample, which led to low statistical power and
wide confidence intervals, particularly in the logistic re-
gression analysis. Furthermore, correction for multiple
testing was not done.
A few concerns are related to missing values in some
of our variables. We rated dropout from treatment only
if a treatment strategy was adequate according to the
case records. Since the case records were not always
comprehensive in this respect, the variable concerning
treatment dropouts contains many (27) missing values.
We faced the same problem approximating the duration
of the depressive episode (21 missing values), which was
done retrospectively based on information in the inter-
view and case records.
A psychotherapeutic session was defined as a visit with
a psychiatrist, psychologist or psychotherapist in all set-
tings or other professional in a psychiatric clinic. There-
fore, according to our definition the professional was
not necessarily a psychotherapist and we could not
evaluate the duration of sessions. Thus psychotherapy in
this article means psychosocial support broadly, and we
cannot draw conclusions on the availability of actual
psychotherapy on the basis of this study. It is also
remarkable that minimally adequate treatment only sig-
nifies that the minimum criterion for treatment
adequacy is reached; it does not mean optimal treat-
ment, which would mean that every effort according to
depression treatment algorithms was made in order to
achieve full symptomatic remission [63].
The Mental Health in Early Adulthood in Finland
(MEAF) study was done in 2003–2005 i.e. about ten
years ago. After the years of the survey there have been
changes in the health care system as well as medication
in Finland, which means that figures of minimally ad-
equate treatment may be different today. Probably, the
situation has improved: based on official statistics, the
use of antidepressants and the number of psychiatric
outpatient visits have increased.
Conclusions
A lack of adequate treatment of depressive disorders is
an ongoing problem, although our results on treatments
among young adults are better than in most previous
studies and encouraging in this respect. Delays in help-
seeking and discontinuation of treatment seem to create
a barrier to proper care. It is alarming that dropout is
related to individuals with less education and suicidality,
who are otherwise also persons at greatest risk of
complications and social exclusion. These groups
present a challenge to future health care and more ef-
forts are needed to outreach and motivate them to
receive effective treatment.Additional files
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